A study from MD Anderson Cancer Center reports that measuring circulating osteoprotegerin may offer a less invasive method to detect and monitor bone metastases in medullary thyroid cancer patients with RET mutations.
Ataraxis AI’s laboratory has received CAP accreditation and a California clinical lab license, expanding clinician access to its AI-powered breast cancer platform.
Craif Inc has raised $34 million in Series D funding to support a US launch of its urine-based cancer test, expand San Diego lab operations, and advance a pancreatic cancer study and regulatory filing in Japan.
Tel Aviv University researchers have developed a low-cost blood test that detects lung cancer by analyzing optical DNA fingerprints, achieving 93.1% sensitivity and 90.3% specificity.
Read More
Researchers at MUSC Hollings Cancer Center have developed the ADLiB liquid biopsy platform, which uses machine learning to prioritize lymphoma diagnosis, identifying high-risk patients with up to 95% accuracy.
Read More
The FDA has approved Labcorp’s PGDx elio tissue complete CDx, a kit-based NGS companion diagnostic, to identify BRAF variants and guide targeted therapy selection for patients with advanced melanoma.
Read More
The FDA will review GRAIL’s Premarket Approval application for the Galleri multi-cancer early detection blood test on Sept 23, 2026, evaluating data from the PATHFINDER 2 and NHS-Galleri studies.
Read More
Personalis has received UKCA marking for its NeXT Personal Dx test, enabling clinical use of its minimal residual disease detection technology across Great Britain, the company announced.
Read More
VolitionRx has published peer-reviewed data on its Capture-Seq technology, reporting over 99% pure ctDNA isolation from plasma and 95% detection of early-stage cancers in validation cohorts.
Read More
Caris Life Sciences has launched in-house PTEN IHC testing to identify prostate cancer patients eligible for FDA-approved, biomarker-guided therapy, supporting precision treatment for PTEN-deficient mAPMN/S prostate cancer.
Read More
Cancer Cell Diagnostics has launched the CellSight DNA test, a liquid biopsy that isolates intact circulating tumor cells for genomic profiling from a single blood draw, enabling analysis of over 500 genes and key biomarkers.
Read More
Concert has issued a coverage policy deeming the EsoGuard Esophageal DNA Test medically necessary for eligible patients, with multiple client health plans now adopting the policy.
Read More
SOPHiA GENETICS and AstraZeneca have signed a multi-year agreement to develop and deploy decentralized companion diagnostics for solid tumors and blood cancers, aiming to expand local lab access to precision oncology testing.
Read More
Labcorp is offering nationwide access to Roche’s FDA-approved VENTANA PTEN (SP218) RxDx Assay, the first IHC companion diagnostic to identify PTEN protein loss in prostate cancer and guide eligibility for combination therapy with capivasertib.
Read More
Clinical labs are adopting broader cancer diagnostics—including whole-genome sequencing and multi-omic testing—to deliver more comprehensive molecular insights and improve disease monitoring.
Read More
Researchers at Johns Hopkins validated an AI-powered blood test that accurately detects liver cancer in diverse populations, using the DELFI platform to analyze cell-free DNA fragments.
Read More
GenomOncology and PacBio have introduced an integrated workflow for somatic whole-genome sequencing in oncology, combining PacBio’s HiFi WGS analysis with GenomOncology’s reporting platform for standardized clinical lab reporting.
Read More
A Johns Hopkins study finds that a single liquid biopsy within nine weeks of immunotherapy start can predict long-term survival in advanced lung cancer, providing results months earlier than standard imaging.
Read More